{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:37:14Z","timestamp":1787341034064,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Aberrant activation of the RAS-RAF-MEK-ERK signaling pathway contributes to numerous malignancies, congenital syndromes, and cardiovascular disorders, establishing MEK inhibitors (MEKi) as crucial therapeutic agents. MEKi demonstrate substantial clinical benefit as monotherapy (e.g., NF1-associated tumors) or combination therapy (e.g., melanoma, glioma, congenital RASopathies). Cardiovascular adverse events, primarily asymptomatic reductions in left ventricular ejection fraction (LVEF), have prompted intensive echocardiographic monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Emerging evidence indicates that isolated mild LVEF decreases rarely progress to symptomatic heart failure, raising concerns about unnecessary treatment interruptions driven by overly rigorous imaging protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Integrating cardiac biomarkers into monitoring strategies could offer a more pragmatic approach, guiding echocardiographic evaluations based on biomarker elevation or symptoms. Expert recommendations advocate personalized, risk-adapted surveillance frameworks. High-risk patients include those with baseline cardiovascular conditions, abnormal biomarker profiles, or significant clinical symptoms. Normal-risk patients can be safely monitored clinically, reserving imaging for biomarker changes or symptom onset. Prospective studies should seek to validate these recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01814-2","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:20:29Z","timestamp":1787293229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1476-5808","authenticated-orcid":false,"given":"Jondavid","family":"Menteer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devorah","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Maraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Klesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Ambady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"4","key":"1814_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","volume":"17","author":"M Banks","year":"2017","unstructured":"Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol. 2017;17(4):487\u201393. https:\/\/doi.org\/10.1007\/s12012-017-9425-z.","journal-title":"Cardiovasc Toxicol"},{"issue":"20","key":"1814_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205059","volume":"13","author":"M Dillon","year":"2021","unstructured":"Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers (Basel). 2021;13(20):5059. https:\/\/doi.org\/10.3390\/cancers13205059.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1814_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1947601911412376","volume":"2","author":"S Gysin","year":"2011","unstructured":"Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011;2(3):359\u201372. https:\/\/doi.org\/10.1177\/1947601911412376.","journal-title":"Genes Cancer"},{"issue":"7","key":"1814_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287\u201392. https:\/\/doi.org\/10.1242\/jcs.182873.","journal-title":"J Cell Sci"},{"issue":"41","key":"1814_CR5","doi-asserted-by":"publisher","first-page":"14087","DOI":"10.1523\/JNEUROSCI.3242-12.2012","volume":"32","author":"DH Gutmann","year":"2012","unstructured":"Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci. 2012;32(41):14087\u201393. https:\/\/doi.org\/10.1523\/JNEUROSCI.3242-12.2012.","journal-title":"J Neurosci"},{"issue":"7","key":"1814_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1212\/wnl.56.7.827","volume":"56","author":"M Ruggieri","year":"2001","unstructured":"Ruggieri M, Packer RJ. Why do benign astrocytomas become malignant in NF1? Neurology. 2001;56(7):827\u20139. https:\/\/doi.org\/10.1212\/wnl.56.7.827.","journal-title":"Neurology"},{"issue":"1","key":"1814_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","volume":"123","author":"VC Williams","year":"2009","unstructured":"Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124\u201333. https:\/\/doi.org\/10.1542\/peds.2007-3204.","journal-title":"Pediatrics"},{"issue":"8","key":"1814_CR8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/humu.20748","volume":"29","author":"Y Aoki","year":"2008","unstructured":"Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992\u20131006. https:\/\/doi.org\/10.1002\/humu.20748.","journal-title":"Hum Mutat"},{"issue":"6","key":"1814_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","volume":"110","author":"IS Harris","year":"2004","unstructured":"Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 2004;110(6):718\u201323. https:\/\/doi.org\/10.1161\/01.CIR.0000138190.50127.6A.","journal-title":"Circulation"},{"key":"1814_CR10","doi-asserted-by":"publisher","unstructured":"Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270(39):23173\u20138. https:\/\/doi.org\/10.1074\/jbc.270.39.23173.","DOI":"10.1074\/jbc.270.39.23173"},{"issue":"Pt 6","key":"1814_CR11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","volume":"111","author":"SM Huson","year":"1988","unstructured":"Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355\u201381. https:\/\/doi.org\/10.1093\/brain\/111.6.1355.","journal-title":"Brain"},{"issue":"1","key":"1814_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005;141(1):71\u20134. https:\/\/doi.org\/10.1001\/archderm.141.1.71.","journal-title":"Arch Dermatol"},{"key":"1814_CR13","unstructured":"Children\u2019s Tumor Foundation. New and Improved: The Way to Talk About NF. 2023. https:\/\/www.ctf.org\/news\/new-and-improved-the-way-to-talk-about-nf\/. Accessed 22 April 2025."},{"issue":"15","key":"1814_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1912735.","journal-title":"N Engl J Med"},{"issue":"6","key":"1814_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43(6):716\u201329. https:\/\/doi.org\/10.1200\/JCO.24.01034.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1814_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18632\/oncotarget.240","volume":"2","author":"WH Chappell","year":"2011","unstructured":"Chappell WH, Steelman LS, Long JM, et al. Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2(3):135\u201364. https:\/\/doi.org\/10.18632\/oncotarget.240.","journal-title":"Oncotarget"},{"issue":"7","key":"1814_CR17","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1074\/jbc.272.7.4378","volume":"272","author":"R Marais","year":"1997","unstructured":"Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 1997;272(7):4378\u201383. https:\/\/doi.org\/10.1074\/jbc.272.7.4378.","journal-title":"J Biol Chem"},{"issue":"9","key":"1814_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.18632\/oncotarget.652","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Chappell WH, et al. Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954\u201387. https:\/\/doi.org\/10.18632\/oncotarget.652.","journal-title":"Oncotarget"},{"issue":"22","key":"1814_CR19","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291\u2013310. https:\/\/doi.org\/10.1038\/sj.onc.1210422.","journal-title":"Oncogene"},{"issue":"6","key":"1814_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367. https:\/\/doi.org\/10.1016\/s0092-8674(04)00215-6.","journal-title":"Cell"},{"issue":"6892","key":"1814_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"7","key":"1814_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517\u201331. https:\/\/doi.org\/10.1038\/nrm2438.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"1814_CR23","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1016\/j.bmcl.2012.07.082","volume":"22","author":"W Wang","year":"2012","unstructured":"Wang W, Fang G, Rudolph J. Ras inhibition via direct Ras binding\u2014is there a path forward? Bioorg Med Chem Lett. 2012;22(18):5766\u201376. https:\/\/doi.org\/10.1016\/j.bmcl.2012.07.082.","journal-title":"Bioorg Med Chem Lett"},{"key":"1814_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/bs.apcsb.2020.05.003","volume":"122","author":"A Sayyed-Ahmad","year":"2020","unstructured":"Sayyed-Ahmad A, Gorfe AA. How to make an undruggable enzyme druggable: lessons from ras proteins. Adv Protein Chem Struct Biol. 2020;122:181\u2013202. https:\/\/doi.org\/10.1016\/bs.apcsb.2020.05.003.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"8","key":"1814_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nchembio.1560","volume":"10","author":"J Spiegel","year":"2014","unstructured":"Spiegel J, Cromm PM, Zimmermann G, Grossmann TN, Waldmann H. Small-molecule modulation of Ras signaling. Nat Chem Biol. 2014;10(8):613\u201322. https:\/\/doi.org\/10.1038\/nchembio.1560.","journal-title":"Nat Chem Biol"},{"key":"1814_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2013.12.004","volume":"11","author":"HE Haarberg","year":"2014","unstructured":"Haarberg HE, Smalley KS. Resistance to Raf inhibition in cancer. Drug Discov Today Technol. 2014;11:27\u201332. https:\/\/doi.org\/10.1016\/j.ddtec.2013.12.004.","journal-title":"Drug Discov Today Technol"},{"issue":"15","key":"1814_CR27","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-16-0396","volume":"76","author":"D Oddo","year":"2016","unstructured":"Oddo D, Sennott EM, Barault L, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 2016;76(15):4504\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0396.","journal-title":"Cancer Res"},{"issue":"7","key":"1814_CR28","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","volume":"11","author":"C Adamopoulos","year":"2021","unstructured":"Adamopoulos C, Ahmed TA, Tucker MR, et al. Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling. Cancer Discov. 2021;11(7):1716\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1351.","journal-title":"Cancer Discov"},{"issue":"2","key":"1814_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1203421.","journal-title":"N Engl J Med"},{"issue":"7466","key":"1814_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12441","volume":"501","author":"G Hatzivassiliou","year":"2013","unstructured":"Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013;501(7466):232\u20136. https:\/\/doi.org\/10.1038\/nature12441.","journal-title":"Nature"},{"issue":"12","key":"1814_CR31","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1884\u2013901. https:\/\/doi.org\/10.1093\/annonc\/mdz411.","journal-title":"Ann Oncol"},{"issue":"5","key":"1814_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.12010","volume":"167","author":"R Sinha","year":"2012","unstructured":"Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167(5):987\u201394. https:\/\/doi.org\/10.1111\/bjd.12010.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1814_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122\u201336. https:\/\/doi.org\/10.1177\/1758834014566428.","journal-title":"Ther Adv Med Oncol"},{"issue":"6385","key":"1814_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/358417a0","volume":"358","author":"JM Kyriakis","year":"1992","unstructured":"Kyriakis JM, App H, Zhang XF, et al. Raf-1 activates MAP kinase-kinase. Nature. 1992;358(6385):417\u201321. https:\/\/doi.org\/10.1038\/358417a0.","journal-title":"Nature"},{"issue":"6435","key":"1814_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/364308a0","volume":"364","author":"XF Zhang","year":"1993","unstructured":"Zhang XF, Settleman J, Kyriakis JM, et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature. 1993;364(6435):308\u201313. https:\/\/doi.org\/10.1038\/364308a0.","journal-title":"Nature"},{"issue":"1","key":"1814_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1814_CR37","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","volume":"20","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20(8):2035\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2054.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1814_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","volume":"73","author":"CJ Wright","year":"2013","unstructured":"Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013;73(11):1245\u201354. https:\/\/doi.org\/10.1007\/s40265-013-0096-1.","journal-title":"Drugs"},{"issue":"3","key":"1814_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9(3):329\u201341. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1321.","journal-title":"Cancer Discov"},{"issue":"15","key":"1814_CR40","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey D, Demko S, Sinha A, et al. FDA approval summary: selumetinib for plexiform neurofibroma. Clin Cancer Res. 2021;27(15):4142\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-5032.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1814_CR41","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hernaiz Driever P, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e305\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(20)30064-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1814_CR42","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.res.83.6.594","volume":"83","author":"H Kai","year":"1998","unstructured":"Kai H, Muraishi A, Sugiu Y, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998;83(6):594\u2013601. https:\/\/doi.org\/10.1161\/01.res.83.6.594.","journal-title":"Circ Res"},{"key":"1814_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1475143","volume":"13","author":"I De Brouchoven","year":"2025","unstructured":"De Brouchoven I, Lorand J, Bofferding L, Sorlin A, Van Damme A, Danhaive O. Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. Front Pediatr. 2025;13:1475143. https:\/\/doi.org\/10.3389\/fped.2025.1475143.","journal-title":"Front Pediatr"},{"issue":"3","key":"1814_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","volume":"164","author":"JD Wilkinson","year":"2012","unstructured":"Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.018.","journal-title":"Am Heart J"},{"issue":"4","key":"1814_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/MAT.0000000000001133","volume":"66","author":"A Lorts","year":"2020","unstructured":"Lorts A, Smyth L, Gajarski RJ, et al. The creation of a pediatric health care learning network: the ACTION quality improvement collaborative. ASAIO J. 2020;66(4):441\u20136. https:\/\/doi.org\/10.1097\/MAT.0000000000001133.","journal-title":"ASAIO J"},{"issue":"1","key":"1814_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/cvr\/cvp040","volume":"82","author":"S Dhingra","year":"2009","unstructured":"Dhingra S, Sharma AK, Arora RC, Slezak J, Singal PK. IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. Cardiovasc Res. 2009;82(1):59\u201366. https:\/\/doi.org\/10.1093\/cvr\/cvp040.","journal-title":"Cardiovasc Res"},{"issue":"16","key":"1814_CR47","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","volume":"109","author":"DJ Lips","year":"2004","unstructured":"Lips DJ, Bueno OF, Wilkins BJ, et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938\u201341. https:\/\/doi.org\/10.1161\/01.CIR.0000127126.73759.23.","journal-title":"Circulation"},{"issue":"2","key":"1814_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cardiores.2006.01.023","volume":"70","author":"K Naitoh","year":"2006","unstructured":"Naitoh K, Ichikawa Y, Miura T, et al. MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res. 2006;70(2):374\u201383. https:\/\/doi.org\/10.1016\/j.cardiores.2006.01.023.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1814_CR49","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, Mahabadi AA, Michel L, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8890.","journal-title":"JAMA Netw Open"},{"issue":"20","key":"1814_CR50","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1406037.","journal-title":"N Engl J Med"},{"issue":"8","key":"1814_CR51","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","volume":"13","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70269-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1814_CR52","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00246-022-02842-y","volume":"43","author":"NJ Robison","year":"2022","unstructured":"Robison NJ, Su JA, Fang MJ, Malvar J, Menteer J. Cardiac function in children and young adults treated with MEK inhibitors: a retrospective cohort study. Pediatr Cardiol. 2022;43(6):1223\u20138. https:\/\/doi.org\/10.1007\/s00246-022-02842-y.","journal-title":"Pediatr Cardiol"},{"issue":"6\u20137","key":"1814_CR53","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.acvd.2020.03.014","volume":"113","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Font J, Bejan-Angoulvant T, et al. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and\/or mitogen-activated extracellular signal-regulated kinase inhibitors: a mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Arch Cardiovasc Dis. 2020;113(6\u20137):420\u201332. https:\/\/doi.org\/10.1016\/j.acvd.2020.03.014.","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"1814_CR54","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/cam4.3938","volume":"10","author":"A Guha","year":"2021","unstructured":"Guha A, Jain P, Fradley MG, et al. Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries. Cancer Med. 2021;10(12):3862\u201372. https:\/\/doi.org\/10.1002\/cam4.3938.","journal-title":"Cancer Med"},{"issue":"9","key":"1814_CR55","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1814_CR56","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1814_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1412690.","journal-title":"N Engl J Med"},{"issue":"20","key":"1814_CR58","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1408868.","journal-title":"N Engl J Med"},{"issue":"21","key":"1814_CR59","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1200\/JCO.2012.47.0104","volume":"31","author":"KM Mahoney","year":"2013","unstructured":"Mahoney KM, Ackerman A, Cho DC, McDermott DF, Peters T, Atkins MB. Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol. 2013;31(21):e364\u20136. https:\/\/doi.org\/10.1200\/JCO.2012.47.0104.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1814_CR60","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3390\/cancers17111755","volume":"17","author":"MA Barbieri","year":"2025","unstructured":"Barbieri MA, Russo G, Cicala G, et al. Cardiovascular safety profile of BRAF and MEK inhibitors in melanoma: FAERS data through a retrospective disproportionality analysis (2014\u20132023). Cancers (Basel). 2025;17(11):1755. https:\/\/doi.org\/10.3390\/cancers17111755.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"1814_CR61","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1210093.","journal-title":"N Engl J Med"},{"issue":"3","key":"1814_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3):e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491.","journal-title":"ESMO Open"},{"issue":"9","key":"1814_CR63","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.res.0000038488.38975.1a","volume":"91","author":"OF Bueno","year":"2002","unstructured":"Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1\/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91(9):776\u201381. https:\/\/doi.org\/10.1161\/01.res.0000038488.38975.1a.","journal-title":"Circ Res"},{"issue":"2","key":"1814_CR64","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1083\/jcb.142.2.523","volume":"142","author":"A Clerk","year":"1998","unstructured":"Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine:a role in cardiac myocyte hypertrophy? J Cell Biol. 1998;142(2):523\u201335. https:\/\/doi.org\/10.1083\/jcb.142.2.523.","journal-title":"J Cell Biol"},{"issue":"47","key":"1814_CR65","doi-asserted-by":"publisher","first-page":"28092","DOI":"10.1074\/jbc.270.47.28092","volume":"270","author":"J Gillespie-Brown","year":"1995","unstructured":"Gillespie-Brown J, Fuller SJ, Bogoyevitch MA, Cowley S, Sugden PH. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. J Biol Chem. 1995;270(47):28092\u20136. https:\/\/doi.org\/10.1074\/jbc.270.47.28092.","journal-title":"J Biol Chem"},{"issue":"6","key":"1814_CR66","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/01.res.78.6.954","volume":"78","author":"PE Glennon","year":"1996","unstructured":"Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller SJ, Sugden PH. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res. 1996;78(6):954\u201361. https:\/\/doi.org\/10.1161\/01.res.78.6.954.","journal-title":"Circ Res"},{"issue":"3","key":"1814_CR67","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2006.05.005","volume":"48","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol. 2006;48(3):556\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2006.05.005.","journal-title":"J Am Coll Cardiol"},{"key":"1814_CR68","doi-asserted-by":"publisher","unstructured":"Silberbach M, Gorenc T, Hershberger RE, Stork PJ, Steyger PS, Roberts CT Jr. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem. 1999;274(35):24858\u201364. https:\/\/doi.org\/10.1074\/jbc.274.35.24858.","DOI":"10.1074\/jbc.274.35.24858"},{"issue":"8","key":"1814_CR69","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1161\/CIRCRESAHA.109.213199","volume":"106","author":"JM Streicher","year":"2010","unstructured":"Streicher JM, Ren S, Herschman H, Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 2010;106(8):1434\u201343. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.213199.","journal-title":"Circ Res"},{"issue":"35","key":"1814_CR70","doi-asserted-by":"publisher","first-page":"14074","DOI":"10.1073\/pnas.0610906104","volume":"104","author":"NH Purcell","year":"2007","unstructured":"Purcell NH, Wilkins BJ, York A, et al. Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A. 2007;104(35):14074\u20139. https:\/\/doi.org\/10.1073\/pnas.0610906104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1814_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00125817-200205000-00002","volume":"4","author":"JM Friedman","year":"2002","unstructured":"Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4(3):105\u201311. https:\/\/doi.org\/10.1097\/00125817-200205000-00002.","journal-title":"Genet Med"},{"issue":"9","key":"1814_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090675","volume":"10","author":"V Pinna","year":"2019","unstructured":"Pinna V, Daniele P, Calcagni G, et al. Prevalence, type, and molecular spectrum of NF1 mutations in patients with neurofibromatosis type 1 and congenital heart disease. Genes. 2019;10(9):675. https:\/\/doi.org\/10.3390\/genes10090675.","journal-title":"Genes"},{"issue":"8","key":"1814_CR73","doi-asserted-by":"publisher","first-page":"714","DOI":"10.5543\/tkda.2015.27557","volume":"43","author":"F Incecik","year":"2015","unstructured":"Incecik F, Herguner OM, Alinc Erdem S, Altunbasak S. Neurofibromatosis type 1 and cardiac manifestations. Turk Kardiyol Dern Ars. 2015;43(8):714\u20136. https:\/\/doi.org\/10.5543\/tkda.2015.27557.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"5","key":"1814_CR74","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1067\/mhj.2002.122121","volume":"143","author":"MA Tedesco","year":"2002","unstructured":"Tedesco MA, Di Salvo G, Natale F, et al. The heart in neurofibromatosis type 1: an echocardiographic study. Am Heart J. 2002;143(5):883\u20138. https:\/\/doi.org\/10.1067\/mhj.2002.122121.","journal-title":"Am Heart J"},{"issue":"3","key":"1814_CR75","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCRESAHA.109.201509","volume":"105","author":"J Xu","year":"2009","unstructured":"Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res. 2009;105(3):304\u201311. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.201509.","journal-title":"Circ Res"},{"issue":"3","key":"1814_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000047366","volume":"95","author":"S Verma","year":"2001","unstructured":"Verma S, Ahmed S, Gudapati SB, King DW, Meador KJ, Ahmed R. Arrhythmias in neurofibromatosis. A case report and review of the literature. Cardiology. 2001;95(3):167\u20139. https:\/\/doi.org\/10.1159\/000047366.","journal-title":"Cardiology"},{"issue":"7","key":"1814_CR77","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10554-024-03125-8","volume":"40","author":"L Kapusta","year":"2024","unstructured":"Kapusta L, Beer G, Rothschild E, et al. Cardiac screening in pediatric patients with neurofibromatosis type 1: similarities with Noonan syndrome? Int J Cardiovasc Imaging. 2024;40(7):1475\u201382. https:\/\/doi.org\/10.1007\/s10554-024-03125-8.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"1814_CR78","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cge.12072","volume":"84","author":"R Nguyen","year":"2013","unstructured":"Nguyen R, Mir TS, Kluwe L, et al. Cardiac characterization of 16 patients with large NF1 gene deletions. Clin Genet. 2013;84(4):344\u20139. https:\/\/doi.org\/10.1111\/cge.12072.","journal-title":"Clin Genet"},{"key":"1814_CR79","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/JMDH.S454921","volume":"17","author":"M Almuqbil","year":"2024","unstructured":"Almuqbil M, Alshaikh FY, Altwaijri W, et al. Epidemiology and outcomes of neurofibromatosis type 1 (NF-1): multicenter tertiary experience. J Multidiscip Healthc. 2024;17:1303\u201314. https:\/\/doi.org\/10.2147\/JMDH.S454921.","journal-title":"J Multidiscip Healthc"},{"key":"1814_CR80","unstructured":"FDA, Cotellic Prescribing Information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206192s005lbl.pdf. Accessed 22 April 2025."},{"issue":"7","key":"1814_CR81","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, et al. NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797\u2013806. https:\/\/doi.org\/10.1200\/JCO.20.02220.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1814_CR82","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/fon-2023-0565","volume":"20","author":"AM Gross","year":"2024","unstructured":"Gross AM, Achee C, Hart SE, et al. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: a plain language summary of SPRINT. Future Oncol. 2024;20(14):877\u201390. https:\/\/doi.org\/10.2217\/fon-2023-0565.","journal-title":"Future Oncol"},{"key":"1814_CR83","unstructured":"FDA, Koselugo Prescribing I. 2020. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2025\/koselugo_uspi.pdf. Accessed 22 April 2025."},{"issue":"9992","key":"1814_CR84","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4.","journal-title":"Lancet"},{"issue":"9","key":"1814_CR85","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s12012-025-10037-z","volume":"25","author":"AM Taha","year":"2025","unstructured":"Taha AM, Odat RM, Moawad WAE, et al. Safety of permissive cardiotoxicity of trastuzumab in patients with breast cancer: a systematic review and meta-analysis. Cardiovasc Toxicol. 2025;25(9):1369\u201380. https:\/\/doi.org\/10.1007\/s12012-025-10037-z.","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"1814_CR86","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jaccao.2024.07.004","volume":"6","author":"JD Bender","year":"2024","unstructured":"Bender JD, Pillay-Smiley N, Hill GD, et al. Cardiac dysfunction in children and young adults treated with MEK inhibitors: a retrospective, single-center study. JACC CardioOncol. 2024;6(5):794\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.004.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1814_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","volume":"4","author":"C Glen","year":"2022","unstructured":"Glen C, Tan YY, Waterston A, et al. Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):1\u201318. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.096.","journal-title":"JACC CardioOncol"},{"issue":"7","key":"1814_CR88","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","volume":"25","author":"LJ Klesse","year":"2020","unstructured":"Klesse LJ, Jordan JT, Radtke HB, et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109\u201316. https:\/\/doi.org\/10.1634\/theoncologist.2020-0069.","journal-title":"Oncologist"},{"issue":"11","key":"1814_CR89","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920.","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"1814_CR90","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"1","key":"1814_CR91","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaccao.2022.10.008","volume":"5","author":"RM Witteles","year":"2023","unstructured":"Witteles RM, Reddy SA. ESC Cardio-Oncology Guidelines: a triumph\u2014but are we overscreening? JACC CardioOncol. 2023;5(1):133\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2022.10.008.","journal-title":"JACC CardioOncol"},{"issue":"16","key":"1814_CR92","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1814_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234083","volume":"16","author":"I Dirven","year":"2024","unstructured":"Dirven I, Pierre E, Vander Mijnsbrugge AS, Vounckx M, Kessels JI, Neyns B. Regorafenib combined with BRAF\/MEK inhibitors for the treatment of refractory melanoma brain metastases. Cancers (Basel). 2024;16(23):4083. https:\/\/doi.org\/10.3390\/cancers16234083.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1814_CR94","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","volume":"5","author":"C Glen","year":"2023","unstructured":"Glen C, Adam S, McDowell K, et al. Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC CardioOncol. 2023;5(5):628\u201337. https:\/\/doi.org\/10.1016\/j.jaccao.2023.04.004.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1814_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26572-6","volume":"12","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12(1):7008. https:\/\/doi.org\/10.1038\/s41467-021-26572-6.","journal-title":"Nat Commun"},{"issue":"6","key":"1814_CR96","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.31889","volume":"125","author":"KR Saab","year":"2019","unstructured":"Saab KR, Mooradian MJ, Wang DY, et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer. 2019;125(6):884\u201391. https:\/\/doi.org\/10.1002\/cncr.31889.","journal-title":"Cancer"},{"issue":"10","key":"1814_CR97","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023;25(10):1883\u201394. https:\/\/doi.org\/10.1093\/neuonc\/noad086.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1814_CR98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.24875\/RMA.23000007","volume":"52","author":"B Mart\u00ednez-Tur\u00e9gano","year":"2024","unstructured":"Mart\u00ednez-Tur\u00e9gano B, Mondrag\u00f3n-Zamora JK, Salazar-\u00c1lvarez A, Mendieta-Azcona C, L\u00f3pez-Guti\u00e9rrez JC, Mar\u00edn-Manzano E. MEK inhibitors in maintenance of a postoperative patient with vasculopathy due to neurofibromatosis type I. SciELO. 2024;52(3):108\u201313. https:\/\/doi.org\/10.24875\/RMA.23000007.","journal-title":"SciELO"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01814-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01814-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01814-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:02:19Z","timestamp":1787338939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01814-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1814"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01814-2","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics Approval and Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Menteer has served on the advisory board for SpringWorks Therapeutics, Inc. Drs Segal, Maraka, and Klesse have served on the advisory boards for SpringWorks Therapeutics, Inc and Alexion. Dr Ambady has served on the advisory boards for SpringWorks Therapeutics, Inc, Servier Pharmaceuticals, and Telix Pharmaceuticals. Dr Fradley has consulted for AstraZeneca, AbbVie, Janssen, Pfizer, and Zoll; has received grants from Medtronic and AstraZeneca; and has served on the advisory board for SpringWorks Therapeutics, Inc.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}